![Budget 2024: Pharma, health, med-tech sectors seek tax tweaks](https://images.assettype.com/fortuneindia%2F2024-07%2Fb9c137e2-d662-4b39-abac-116baef9771f%2FGettyImages-1839797697.jpg?w=300&q=95)
Budget 2024: Pharma, health, med-tech sectors seek tax tweaks
Indian Pharmaceutical Alliance, an association of 23 leading pharma companies, seeks direct and indirect tax benefits from Budget to encourage research and investment in pharma sector
Indian Pharmaceutical Alliance, an association of 23 leading pharma companies, seeks direct and indirect tax benefits from Budget to encourage research and investment in pharma sector
Digitising regulatory submissions is expected to accelerate drug approvals, while new tax benefit policies are anticipated to boost R&D
The industry expects an enhanced healthcare spend of 2.5% of GDP to boost infrastructure and R&D activities.
The IPO of the country’s fourth largest pharma company by domestic sales comprises an offer for the sale of 4 crore equity shares by the promoters and existing investors.
Budget allotted ₹89,160 crore for healthcare sector for FY2024, less than 3% increase from previous year. In FY23, spending on healthcare was only 2.1% of GDP.
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
The domestic formulations market is expected to grow 7-9% this fiscal.